BioCentury
ARTICLE | Clinical News

Y-90 epratuzumab regulatory update

November 17, 2008 8:00 AM UTC

FDA granted Orphan Drug designation to Immunomedics for epratuzumab to treat acute lymphoblastic leukemia (ALL). The humanized mAb against CD22 is in Phase II testing to treat B cell ALL. ...